CSBio CSBio

X
[{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"LG Chem Life Sciences and TransThera Biosciences Ink License Agreement for Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"TransThera Biosciences"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the terms of the agreement, LG Chem will obtain exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025.

            Lead Product(s): TT-01025

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TT-01025

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: LG Chem

            Deal Size: $350.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 18, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY